​

Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?

OverviewForecastRevenueFinancialsChart

Celldex Therapeutics Ownership Summary

Celldex Therapeutics is owned by 104.54% institutional investors, 0.19% insiders. Kynam capital management, lp is the largest institutional shareholder, holding 9.19% of CLDX shares. BB Biotech AG Ord is the top mutual fund, with 4.63% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCelldex Therapeutics104.54%0.19%-4.73%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Kynam capital management, lp6.10M9.19%$157.83M
Wellington management group llp5.80M8.74%$150.05M
Blackrock funding, inc. /de5.51M8.29%$142.44M
Blackrock4.69M7.97%$173.61M
Fmr4.96M7.47%$128.37M
Vanguard group3.95M5.96%$102.31M
Point72 asset management3.89M5.87%$100.74M
Bellevue group3.56M5.36%$92.04M
Commodore capital lp3.03M4.56%$78.34M
State street2.84M4.28%$73.53M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp6.10M11.75%$157.83M
5am venture management497.27K4.71%$12.86M
Propel bio management155.00K4.01%$4.01M
Commodore capital lp3.03M3.82%$78.34M
Tsp capital management group375.93K2.60%$9.73M
Eversept partners, lp1.15M2.06%$29.85M
Novo1.20M2.00%$31.04M
Bellevue group3.56M1.91%$92.04M
Deep track capital, lp2.00M1.44%$51.74M
Vestal point capital, lp1.21M1.41%$31.17M

Top Buyers

HolderShares% AssetsChange
Point72 asset management3.89M0.17%1.09M
Braidwell lp591.69K0.45%591.69K
Wellington management group llp5.80M0.03%567.68K
Eventide asset management1.86M0.79%502.91K
State street2.84M0.00%436.64K

Top Sellers

HolderShares% AssetsChange
T. rowe price investment management---1.70M
Price t rowe associates inc /md/2.38M0.01%-1.44M
Jennison associates---1.32M
Woodline partners lp199.29K0.02%-1.30M
Ecor1 capital---650.00K

New Positions

HolderShares% AssetsChangeValue
Braidwell lp591.69K0.45%591.69K$15.31M
Affinity asset advisors300.00K0.68%300.00K$7.76M
Propel bio management155.00K4.01%155.00K$4.01M
Axa investment managers121.33K0.01%121.33K$3.14M
Simplify asset management85.00K0.04%85.00K$2.20M

Sold Out

HolderChange
Assetmark-1.00
Umb bank, n.a.-2.00
Nelson, van denburg & campbell wealth management group-10.00
Householder group estate & retirement specialist-11.00
Coldstream capital management-12.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251802.27%69,405,041-0.96%1040.94%95-14.41%5031.58%
Jun 30, 20251843.95%72,686,2280.53%1090.92%11325.56%41-22.64%
Mar 31, 2025180-5.76%73,628,401-0.08%1100.90%90-11.76%5510.00%
Dec 31, 2024122-38.69%40,075,962-44.20%600.52%68-28.42%29-47.27%
Sep 30, 20241996.42%71,815,5513.19%1080.78%95-8.65%5514.58%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord3.07M4.63%-
Eventide Gilead N2.38M3.59%-
Vanguard Total Stock Mkt Idx Inv2.14M3.22%-44.27K
Vanguard Health Care Inv2.12M3.19%-2.43M
Vanguard US Total Market Shares ETF2.07M3.11%2.12K
iShares Russell 2000 ETF1.57M2.37%-
US Small-Cap Growth II Equity Comp1.39M2.09%-121.70K
Eventide Healthcare & Life Sciences I1.36M2.04%-
Polar Capital Biotech S Inc1.23M1.84%-
Polar Capital Healthcare Opports Inc1.15M1.73%-

Recent Insider Transactions

DateNameRoleActivityValue
Nov 13, 2025Wright Richard M. Former OfficerSell$1.18M
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$8.17K
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$10.93K
Nov 11, 2024Marucci Anthony S PRESIDENT & CEOBuy$308.43K
Jun 14, 2024Martin Samuel Bates SVP AND CFOSell$608.31K

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q3-2
2025 Q2--
2024 Q41-
2024 Q2-12

CLDX Ownership FAQ

Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 104.54%, followed by 0.19% insiders and -4.73% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 45.24%, which Celldex Therapeutics exceeds.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Kynam capital management, lp (6.1M shares, 9.19%), Wellington management group llp (5.8M shares, 8.74%), and Blackrock funding, inc. /de (5.51M shares, 8.29%). Together, they hold 26.22% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 11.75% of its assets in 6.1M Celldex Therapeutics shares, valued at 157.83M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Celldex Therapeutics shares, with 4.63% of its total shares outstanding invested in 3.07M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools